Packaging for All
March 8, 2019
When considering the elderly, we can’t stop at drug development – packaging needs special consideration too.
0 min read
February 2019
Welcome to the February issue! The elderly are the central focus of our cover feature as we ask how pharma can better meet the diverse needs of older patients. Meanwhile in Upfront, we present an infographic snapshot of drug development in Europe, and researchers also enlighten us about the therapeutic potential of nanoparticles. In Business, George Chressanthis argues that the CVS-Aetna merger will prove a transformative event for pharma, while James Strachan explores the consequences of a “no-deal” Brexit for the drug development industry. We also Sit Down With Steve Arlington, who is facilitating collaborations as President at the Pistoia Alliance.
With Age Comes Challenges But Not Trials
February 27, 2019
The elderly are the biggest users of pharmaceutical products but make up only a small percentage of participants in clinical trials. The reason behind this is obvious: elderly patients are complicated, and deciphering a drug’s benefit-to-harm ratio in complicated patients is challenging. A key focus of Andrew McLachlan’s career is understanding the impact of aging on drug disposition and response to medicines. Today, he is Head of the University of Sydney School of Pharmacy, Dean of Pharmacy, and Program Director of Australia’s National Health and Medical Research Council’s (NHMRC) Centre for Research Excellence in Medicines and Ageing. He’s also a Member of the Order of Australia. We spoke with McLachlan to find out why the needs of the elderly are so often overlooked in drug development.
0 min read
Ask, and Ye Shall Receive
February 25, 2019
Regardless of how Britain leaves the European Union, the global pharma industry must always lobby for positive change.
0 min read
Phasing Out Inefficiency
February 21, 2019
Struggling with process research and development? Find yourself a CRO that knows what it’s doing.
0 min read
Taste the Rainbow
February 20, 2019
The color of a capsule or tablet can have a big impact on compliance and branding, but remember: decisions must be made early to avoid development delays.
0 min read
Who's the Best?
February 19, 2019
Vote now for the top drug development technology of 2018.
0 min read
Solutions in... Drug Development
February 19, 2019
Douglas J. Swirsky, CEO of Rexahn Pharmaceuticals, explains his company’s approach to developing more effective cancer treatments.
0 min read
Mergers and Big Decisions
February 18, 2019
The CVS-Aetna merger could be a transformative event for the pharmaceutical industry. Shrewd negotiating decisions, analytics and real world evidence have never been more important.
0 min read
Medicine Making in Europe
February 14, 2019
EFPIA figures give a snapshot of drug development and innovation in Europe
0 min read
Remembering Stewart Adams OBE
February 13, 2019
The inventor of ibuprofen died on January 30, aged 95.
0 min read
The (Secret) Barrier Breaker
February 13, 2019
Sitting Down With… Steve Arlington, President at the Pistoia Alliance.
0 min read
Facing the Brexit Trial
February 12, 2019
A “no-deal” Brexit poses unique challenges for the drug development and advanced therapy sectors – not least tight timelines and a limited ability to stockpile. Here, we explore the potential pain points and find out what companies can do to prepare.
0 min read
Taking a Byte out of Formulation Development
February 11, 2019
With so much technology at our disposal, it’s time to get smart in formulation by adopting in silico approaches.
0 min read
When Noses Counterattack
January 22, 2019
Mimicking the exomes secreted by nasal cells in response to bacteria could boost drug uptake
0 min read
Tiny Dancers
January 22, 2019
Could observation of waltzing therapeutic nanoparticles help determine drug efficacy?
0 min read
